Cargando…
Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study
OBJECTIVE: To assess the safety, tolerability, and feasibility of adult allogeneic bone marrow–derived mesenchymal precursor cells (MPCs) in type 2 diabetes inadequately controlled with metformin either alone or with one additional oral antidiabetic agent. RESEARCH DESIGN AND METHODS: The study was...
Autores principales: | Skyler, Jay S., Fonseca, Vivian A., Segal, Karen R., Rosenstock, Julio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542273/ https://www.ncbi.nlm.nih.gov/pubmed/26153271 http://dx.doi.org/10.2337/dc14-2830 |
Ejemplares similares
-
Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study
por: Packham, David K., et al.
Publicado: (2016) -
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014) -
Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014) -
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study)
por: Nomoto, Hiroshi, et al.
Publicado: (2022) -
Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System
por: Castle, Jessica R., et al.
Publicado: (2015)